Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 25, 2016 - Issue 2
Submit an article Journal homepage
781
Views
31
CrossRef citations to date
0
Altmetric
Reviews

Potential serotonergic agents for the treatment of schizophrenia

Ricardo P. GarayPharmacology & Therapeutics, Craven, Villemoisson-sur-Orge, FranceCorrespondence[email protected]
,
Michel BourinNeurobiology of Anxiety and Depression, School of Medicine, University of Nantes, Nantes, France
,
Evelyne de PaillettePharmacology & Therapeutics, Craven, Villemoisson-sur-Orge, France
,
Ludovic SamalinCentre Médico-Psychologique B, CHU Clermont-Ferrand, EA 7280, Clermont-Ferrand University, Clermont-Ferrand, France
,
Ahcène HamegPharmacology & Therapeutics, Craven, Villemoisson-sur-Orge, France
&
Pierre-Michel LlorcaCentre Médico-Psychologique B, CHU Clermont-Ferrand, EA 7280, Clermont-Ferrand University, Clermont-Ferrand, France
Pages 159-170 | Received 05 Oct 2015, Accepted 16 Nov 2015, Published online: 15 Dec 2015

Bibliography

  • Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.
  • Tandon R, Gaebel W, Barch DM, et al. Definition and description of schizophrenia in the DSM-5. Schizophr Res. 2013;150:3–10.
  • Leucht S, Burkard T, Henderson J, et al. Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand. 2007;116:317–333.
  • Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2163–2196.
  • Salomon JA, Vos T, Hogan DR, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet. 2012;380:2129–2143.
  • Meltzer HY, Massey BW. The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol. 2011;11:59–67.
  • Hacksell U, Burstein E, McFarland K, et al. On the discovery and development of pimavanserin: a novel drug candidate for Parkinson’s psychosis. Neurochem Res. 2014;39:2008–2017.
  • Meltzer HY, Elkis H, Vanover K, et al. Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day. Schizophr Res. 2012;141:144–152.

•• Adjunctive pimavanserin reduces undesirable effects of antipsychotic drugs.

  • Abbas A, Roth BL. Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders. Expert Opin Pharmacother. 2008;9:3251–3259.
  • Dunlop J, Watts SW, Barrett JE, et al. Characterization of vabicaserin (SCA-136), a selective 5-hydroxytryptamine 2C receptor agonist. J Pharmacol Exp Ther. 2011;337:673–680.
  • Shen JHQ, Zhao Y, Rosenzweig-Lipson S, et al. A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia. J Psychiat Res. 2014;53:14–22.

• The 5-HT2C agonist vabicaserin showed antipsychotic efficacy with less side effects than olanzapine.

  • Rosenzweig-Lipson S, Comery TA, Marquis KL, et al. 5-HT2C agonists as therapeutics for the treatment of schizophrenia. Handb Exp Pharmacol. 2012;213:147–165.
  • Kishi T, Mukai T, Matsuda Y, et al. Selective serotonin 3 receptor antagonist treatment for schizophrenia: meta-analysis and systematic review. Neuromol Med. 2014;16:61–69.

•• 5-HT3 antagonists reduce negative symptoms and/or cognitive impairments in schizophrenia.

  • Noroozian M, Ghasemi S, Hosseini S-M-R, et al. A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia. Psychopharmacology. 2013;228:595–602.
  • Akhondzadeh S, Mohammadi N, Noroozian M, et al. Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial. Schizophr Res. 2009;107:206–212.
  • Ye JH, Ponnudurai R, Schaefer R. Ondansetron: a selective 5-HT(3) receptor antagonist and its applications in CNS-related disorders. CNS Drug Rev. 2001;7:199–213.
  • Khodaie-Ardakani M-R, Seddighi S, Modabbernia A, et al. Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study. J Psychiatric Res. 2013;47:472–478.
  • Zhang Z-J, Kang W-H, Li Q, et al. Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study. Schizophr Res. 2006;88:102–110.
  • Shiina A, Shirayama Y, Niitsu T, et al. A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia. Ann Gen Psychiatry. 2010;9:27.
  • Zhang XY, Liu L, Liu S, et al. Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia. Am J Psychiatry. 2012;169:974–981.
  • Levkovitz Y, Arnest G, Mendlovic S, et al. The effect of ondansetron on memory in schizophrenic patients. Brain Res Bull. 2005;65:291–295.
  • Bennett AC, Vila TM. The role of ondansetron in the treatment of schizophrenia. Ann Pharmacother. 2010;44:1301–1306.
  • Fone KCF. An update on the role of the 5-hydroxytryptamine6 receptor in cognitive function. Neuropharmacol. 2008;55:1015–1022.
  • Mitchell ES, Neumaier JF. 5-HT6 receptors: a novel target for cognitive enhancement. Pharmacol Therap. 2005;108:320–333.
  • Morozova MA, Lepilkina TA, Rupchev GE, et al. Add-on clinical effects of selective antagonist of 5HT6 receptors AVN-211 (CD-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: pilot study. CNS Spectr. 2014;19:316–323.
  • Mohler E, Baker P, Gannon K, et al. The effects of PRX-07034, a novel 5-HT6 antagonist, on cognitive flexibility and working memory in rats. Psychopharmacology. 2012;220:687–696.
  • Garay RP, Samalin L, Hameg A, et al. Investigational drugs for anxiety in patients with schizophrenia. Exp Opin Investig Drugs. 2015;24:507–517.
  • Garay RP, Llorca P-M, Young AH, et al. Bipolar disorder: recent clinical trials and emerging therapies for depressive episodes and maintenance treatment. Drug Discov Today. 2014;19:1792–1800.
  • Avineuro. News and events. 2013 Jul 15. Available from: http://www.avineuro.com
  • Arnt J, Bang-Andersen B, Grayson B, et al. Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol. 2010;13:1021–1033.
  • Galimberti D, Scarpini E. Idalopirdine as a treatment for Alzheimer’s disease. Exp Opin Investig Drugs. 2015;24:981–987.
  • Meltzer HY, Huang M. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. In: Giuseppe Di Giovann VDM, Ennio E, editors. Progress in brain research. Vol. 172. Philadelphia (PA): Elsevier; 2008. p. 177–197.
  • Meltzer HY, Roth BL. Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype–targeted drugs. J Clin Invest. 2013;123:4986–4991.
  • Khilnani G, Khilnani AK. Inverse agonism and its therapeutic significance. Indian J Pharmacol. 2011;43:492–501.
  • Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383:533–540.

• Phase III trial showing efficacy of pimavanserin in Parkinson’s disease psychosis.

  • Friedman JH. Pimavanserin for the treatment of Parkinson’s disease psychosis. Expert Opin Pharmacother. 2013;14:1969–1975.
  • Hovelsø N, Sager TN, Mørk A. Combination of escitalopram and a 5-HT1A receptor antagonist selectively decreases the extracellular levels of dopamine in the nucleus accumbens relative to striatum through 5-HT2C receptor stimulation; suggestive of antipsychotic potential. Pharmacol Biochem Behav. 2011;97:479–485.
  • Liu J, Ogden A, Comery TA, et al. Prediction of efficacy of vabicaserin, a 5-HT(2C) agonist, for the treatment of schizophrenia using a quantitative systems pharmacology model. CPT Pharmacometrics Syst Pharmacol. 2014;3:e111.
  • Barnes NM, Hales TG, Lummis SCR, et al. The 5-HT3 receptor – the relationship between structure and function. Neuropharmacology. 2009;56:273–284.
  • Funahashi M, Mitoh Y, Matsuo R. Activation of presynaptic 5-HT3 receptors facilitates glutamatergic synaptic inputs to area postrema neurons in rat brain slices. Methods Find Exp Clin Pharmacol. 2004;26:615–622.
  • Kurhe YV, Radhakrishnan M, Thangaraj D, et al. Anti-anxiety effect of a novel 5-HT(3) receptor antagonist N-(benzo[d]thiazol-2-yl)-3-ethoxyquinoxalin-2-carboxamide (6k) using battery tests for anxiety in mice. Indian J Pharmacol. 2014;46:100–104.
  • Kurhe Y, Mahesh R. Mechanisms linking depression co-morbid with obesity: an approach for serotonergic type 3 receptor antagonist as novel therapeutic intervention. Asian J Psychiatry. 2015 Jul 18. [Epub ahead of print].
  • Macor JE, Gurley D, Lanthorn T, et al. The 5-HT3 antagonist tropisetron (ICS 205-930) is a potent and selective α7 nicotinic receptor partial agonist. Bioorg Med Chem Lett. 2001;11:319–321.

• The 5-HT3 antagonist tropisetron is a potent α7 nicotinic receptor partial agonist, an action that can be translated into procognitive effects.

  • Monsma FJ, Shen Y, Ward RP, et al. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol. 1993;43:320–327.
  • Ward RP, Hamblin MW, Lachowicz JE, et al. Localization of serotonin subtype 6 receptor messenger RNA in the rat brain by in situ hybridization histochemistry. Neuroscience. 1995;64:1105–1111.
  • Dawson LA, Nguyen HQ, Li P. The 5-HT6 receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus. Neuropsychopharmacology. 2001;25:662–668.
  • Lacroix LP, Dawson LA, Hagan JJ, et al. 5-HT6 receptor antagonist SB-271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex. Synapse. 2004;51:158–164.
  • Kauffman MG. EPIX pharmaceuticals announces statistically significant results in cognitive function from phase 1b clinical trial of novel 5-HT6 drug candidate. Reported to Business Wire. 2007. Available from: http://www.businesswire.com
  • Finn JF. Epix Pharmaceuticals, Inc. Announces a successful auction sale of five drug program intellectual properties on September 30, 2009. The Gaea Times. 2009. Available from: http://pr.gaeatimes.com
  • Neill JC, Barnes S, Cook S, et al. Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol Therap. 2010;128:419–432.
  • Gainetdinov RR, Mohn AR, Caron MG. Genetic animal models: focus on schizophrenia. Trends Neurosci. 2001;24:527–533.
  • Jones CA, Watson DJG, Fone KCF. Animal models of schizophrenia. Br J Pharmacol. 2011;164:1162–1194.
  • Yamazaki M, Harada K, Yamamoto N, et al. ASP5736, a novel 5-HT5A receptor antagonist, ameliorates positive symptoms and cognitive impairment in animal models of schizophrenia. Eur Neuropsychopharmacol. 2014;24:1698–1708.

• 5-HT5A receptor antagonists might be effective for cognitive impairment.

  • Yamazaki M, Okabe M, Yamamoto N, et al. Novel 5-HT5A receptor antagonists ameliorate scopolamine-induced working memory deficit in mice and reference memory impairment in aged rats. J Pharmacol Sci. 2015;127:362–369.

• 5-HT5A receptor antagonists might be effective for cognitive impairment.

  • Kassai F, Schlumberger C, Kedves R, et al. Effect of 5-HT5A antagonists in animal models of schizophrenia, anxiety and depression. Behav Pharmacol. 2012;23:397–406.
  • Nikiforuk A. Targeting the serotonin 5-HT(7) receptor in the search for treatments for CNS disorders: rationale and progress to date. CNS Drugs. 2015;29:265–275.
  • Waters KA, Stean TO, Hammond B, et al. Effects of the selective 5-HT7 receptor antagonist SB-269970 in animal models of psychosis and cognition. Behav Brain Res. 2012;228:211–218.
  • Galici R, Boggs JD, Miller KL, et al. Effects of SB-269970, a 5-HT7 receptor antagonist, in mouse models predictive of antipsychotic-like activity. Behav Pharmacol. 2008;19:153–159.
  • Pouzet B, Didriksen M, Arnt J. Effects of the 5-HT7 receptor antagonist SB-258741 in animal models for schizophrenia. Pharmacol Biochem Behav. 2002;71:655–665.
  • Horisawa T, Ishibashi T, Nishikawa H, et al. The effects of selective antagonists of serotonin 5-HT7 and 5-HT1A receptors on MK-801-induced impairment of learning and memory in the passive avoidance and Morris water maze tests in rats: mechanistic implications for the beneficial effects of the novel atypical antipsychotic lurasidone. Behav Brain Res. 2011;220:83–90.
  • Rees S, Den Daas I, Foord S, et al. Cloning and characterisation of the human 5-HT5A serotonin receptor. FEBS Lett. 1994;355:242–246.
  • Thomas DR. 5-HT5A receptors as a therapeutic target. Pharmacol Therap. 2006;111:707–714.
  • Bard JA, Zgombick J, Adham N, et al. Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase. J Biol Chem. 1993;268:23422–23426.
  • Hedlund PB, Sutcliffe JG. Functional, molecular and pharmacological advances in 5-HT7 receptor research. Trends Pharmacol Sci. 2004;25:481–486.
  • Stiedl O, Pappa E, Konradsson-Geuken Å, et al. The role of the serotonin receptor subtypes 5-HT1A and 5-HT7 and its interaction in emotional learning and memory. Frontiers Pharmacol. 2015;6:162. DOI:10.3389/fphar.2015.00162.
  • Abbas AI, Hedlund PB, Huang X-P, et al. Amisulpride is a potent 5-HT(7) antagonist: relevance for antidepressant actions in vivo. Psychopharmacology. 2009;205:119.
  • Horisawa T, Nishikawa H, Toma S, et al. The role of 5-HT7 receptor antagonism in the amelioration of MK-801-induced learning and memory deficits by the novel atypical antipsychotic drug lurasidone. Behav Brain Res. 2013;244:66–69.
  • Foong JPP, Bornstein JC. 5-HT antagonists NAN-190 and SB 269970 block α2-adrenoceptors in the guinea pig. NeuroReport. 2009;20:325–330.
  • Snyder GL, Vanover KE, Zhu H, et al. Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission. Psychopharmacology. 2015;232:605–621.
  • ITCI. Intra-Cellular Therapies’ (ITCI) phase 3 trial of ITI-007 in schizophrenia met primary endpoint. StreetInsidercom [Internet]. 2015 [cited 2015 Dec 1]. Available from: www.streetinsider.com
  • Jancin B. Novel antipsychotic shows early promise. Clinical Psychiatry News. 2013. Available from: http://www.clinicalpsychiatrynews.com
  • Acadia. ACADIA pharmaceuticals advances AM-831 to Phase I clinical development in collaboration with Meiji Seika Pharma. 2011. Available from: http://phxcorporate-irnet
  • Andreasen NC, William T, Carpenter J, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162:441–449.
  • Kishi T, Iwata N. Meta-analysis of noradrenergic and specific serotonergic antidepressant use in schizophrenia. Int J Neuropsychopharmacol. 2014;17:343–354.
  • Terevnikov V, Joffe G, Stenberg J-H. Randomized controlled trials of add-on antidepressants in schizophrenia. Int J Neuropsychopharmacol. 2015;18. DOI:10.1093/ijnp/pyv049.
  • Kishi T, Meltzer HY, Iwata N. Augmentation of antipsychotic drug action by azapirone 5-HT1A receptor partial agonists: a meta-analysis. Int J Neuropsychopharmacol. 2013;16:1259–1266.
  • Rothschild AJ. The evidence-based guide to antipsychotic medications. Arlington (VA): American Psychiatric Publishing; 2010.
  • Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(Suppl 1):1–93.
  • Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951–962.
  • Citrome L. Unmet needs in the treatment of schizophrenia: new targets to help different symptom domains. J Clin Psychiatry. 2014;75(Suppl 1):21–26.

• State of the art of unmet needs in the treatment of schizophrenia.

  • Millier A, Schmidt U, Angermeyer MC, et al. Humanistic burden in schizophrenia: a literature review. J Psychiatric Res. 2014;54:85–93.
  • Kalin M, Kaplan S, Gould F, et al. Social cognition, social competence, negative symptoms and social outcomes: inter-relationships in people with schizophrenia. J Psychiatr Res. 2015;68:254–260.
  • Martin AK, Mowry B, Reutens D, et al. Executive functioning in schizophrenia: unique and shared variance with measures of fluid intelligence. Brain Cogn. 2015;99:57–67.
  • Leucht S. Measurements of response, remission, and recovery in schizophrenia and examples for their clinical application. J Clin Psychiatr. 2014;75(Suppl. 1):8–14.
  • Buchanan RW, Javitt DC, Marder SR, et al. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry. 2007;164:1593–1602.
  • Stauffer VL, Millen BA, Andersen S, et al. Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo. Schizophr Res. 2013;150:434–441.
  • Downing AM, Kinon BJ, Millen BA, et al. A double-blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia. BMC Psychiatry. 2014;14:351.
  • Thomsen MS, Hansen HH, Timmerman DB, et al. Cognitive improvement by activation of alpha7 nicotinic acetylcholine receptors: from animal models to human pathophysiology. Curr Pharm Des. 2010;16:323–343.
  • Barbier AJ, Hilhorst M, Vliet AV, et al. Pharmacodynamics, pharmacokinetics, safety, and tolerability of encenicline, a selective α7 nicotinic receptor partial agonist, in single ascending-dose and bioavailability studies. Clin Ther. 2015;37:311–324.
  • Blower PR. Granisetron: relating pharmacology to clinical efficacy. Support Care Cancer. 2003;11:93–100.
  • Axovant. Axovant’s RVT-101 phase 2b completer analysis demonstrates statistically significant benefits in cognition and function through 48 weeks. PR Newswire. 2015. Available from: http://www.prnewswire
  • Maher-Edwards G, Ascher J, Watson C, et al. 48-week efficacy and tolerability of treatment with SB-742457, a novel 5HT6 receptor antagonist, when added on to donepezil in subjects with mild-to-moderate Alzheimer’s disease (AD). J Alzheimer’s Ass. 2011;7:e5.
  • Herrik KF, Richard N, Garmer M, et al. The 5-HT6 antagonist LU AE58054 potentiates the effects of acetylcholinesterase inhibition on extracellular acetylcholine levels and oscillatory activity in the rat dorsal hippocampus. J Alzheimer’s Ass. 2014;10:P780.
  • Foraster MA, Herrik KF, Richard N, et al. The 5-HT6 receptor antagonist LU AE58054 alone and in combination with donepezil potentiates gamma oscillations in rat medial prefrontal cortex. J Alzheimer’s Ass. 2014;10:780–781.
  • Wilkinson D, Windfeld K, Colding-Jørgensen E. Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer’s disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2014;13:1092–1099.
  • Schneider LS. Idalopirdine for Alzheimer’s disease: written in the stars. Lancet Neurol. 2014;13:1063–1065.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.